-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Acutus Medical, Inc. (NASDAQ:AFIB) Sees Large Decline in Short Interest
Acutus Medical, Inc. (NASDAQ:AFIB) Sees Large Decline in Short Interest
Acutus Medical, Inc. (NASDAQ:AFIB – Get Rating) was the recipient of a significant decline in short interest during the month of December. As of December 30th, there was short interest totalling 899,000 shares, a decline of 15.2% from the December 15th total of 1,060,000 shares. Based on an average daily volume of 547,500 shares, the short-interest ratio is presently 1.6 days. Approximately 4.7% of the shares of the stock are short sold.
Institutional Investors Weigh In On Acutus Medical
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Acutus Medical by 70.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,142,170 shares of the company's stock valued at $1,005,000 after purchasing an additional 470,719 shares during the period. State Street Corp increased its holdings in shares of Acutus Medical by 11.0% in the 1st quarter. State Street Corp now owns 430,865 shares of the company's stock valued at $599,000 after purchasing an additional 42,578 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Acutus Medical in the 1st quarter valued at about $499,000. AQR Capital Management LLC increased its holdings in Acutus Medical by 844.0% in the second quarter. AQR Capital Management LLC now owns 174,352 shares of the company's stock worth $195,000 after buying an additional 155,883 shares during the last quarter. Finally, Mirabella Financial Services LLP acquired a new position in Acutus Medical in the first quarter worth approximately $48,000. 36.32% of the stock is owned by institutional investors and hedge funds.
Get Acutus Medical alerts:Acutus Medical Stock Up 15.4 %
Shares of NASDAQ:AFIB opened at $1.50 on Friday. Acutus Medical has a 1 year low of $0.48 and a 1 year high of $2.49. The company has a market cap of $42.68 million, a PE ratio of -0.48 and a beta of 0.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.12 and a quick ratio of 4.33. The stock's 50-day moving average is $0.98 and its 200 day moving average is $1.05.
Acutus Medical (NASDAQ:AFIB – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. The business had revenue of $3.64 million for the quarter, compared to analysts' expectations of $3.52 million. Acutus Medical had a negative return on equity of 100.62% and a negative net margin of 545.51%. Sell-side analysts anticipate that Acutus Medical will post -2.84 EPS for the current year.About Acutus Medical
(Get Rating)
Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.
Read More
- Get a free copy of the StockNews.com research report on Acutus Medical (AFIB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Acutus Medical,Inc.(納斯達克代碼:AFIB-GET評級)是空頭股數12月份股價大幅下跌的接受者。截至12月30日,空頭股數共有89.9萬股,與12月15日的106萬股相比,下降了15.2%。以日均成交量54.75萬股計算,目前短息比率為1.6天。大約4.7%的股票被賣空。
機構投資者看好Acutus Medical
機構投資者和對沖基金最近買賣了該公司的股票。先鋒集團第三季度增持Acutus Medical股票70.1%。先鋒集團目前持有1,142,170股該公司股票,價值1,005,000美元,在此期間又購買了470,719股。道富集團在第一季度增持了Acutus Medical的股票11.0%。道富銀行目前持有430,865股該公司股票,價值599,000美元,在此期間又購買了42,578股。復興科技有限責任公司在第一季度收購了Acutus Medical的新頭寸,價值約49.9萬美元。AQR資本管理有限責任公司在第二季度增持了Acutus Medical的股份844.0%。AQR Capital Management LLC現在擁有174,352股該公司股票,價值19.5萬美元,上個季度又購買了155,883股。最後,Mirabella Financial Services LLP在第一季度收購了Acutus Medical的一個新頭寸,價值約為4.8萬美元。36.32%的股票由機構投資者和對沖基金持有。
到達Acutus Medical警報:Acutus醫療類股上漲15.4%
納斯達克:AFIB上週五開盤報1.5美元。Acutus Medical的一年低點為0.48美元,一年高位為2.49美元。該公司市值為4,268萬美元,本益比為-0.48,貝塔係數為0.64。該公司的債務權益比為0.59,流動比率為5.12,速動比率為4.33。該股的50日移動均線切入位在0.98美元,200日移動均線切入位在1.05美元。
Acutus Medical(納斯達克:AFIB-GET評級)最近一次發佈季度收益數據是在11月10日星期四。該公司公佈了該季度每股收益(EPS)(0.72美元),比普遍預期的(0.83美元)高出0.11美元。該業務當季營收為364萬美元,高於分析師預期的352萬美元。Acutus Medical的淨資產回報率為負100.62%,淨利潤率為負545.51%。賣方分析師預計,Acutus Medical本年度每股收益將達到2.84歐元。關於Acutus Medical
(獲取評級)
Acutus Medical,Inc.是一家心律不整管理公司,設計、製造和銷售一系列工具,用於在美國和國際上治療各種心律不整的基於導管的消融程式。該公司的產品組合包括新型進入鞘、跨室間隔交叉工具、診斷和標測導管、常規和接觸力消融導管、標測和成像控制臺及附件,以及支持算法和軟件程序。
閱讀更多內容
- 免費獲取StockNews.com關於Acutus Medical的研究報告(AFib)
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車?
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
接受《Acutus醫學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acutus Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧